|
|
|
|
|
Last Trade
|
Last Trade:
$7.92
|
Change:
0.09 (1.15%)
|
Trade Time:
Jan 27
|
Market Cap:
$1.14B
|
|
|
|
|
|
|
Description of Business
|
|
We are a clinical stage immuno-oncology company pioneering the development of
genetically engineered allogeneic T cell therapies for the treatment of cancer.
We are developing a pipeline of off-the-shelf T cell product candidates that are
designed to target and kill cancer cells. Our engineered T cells are allogeneic,
meaning they are derived from healthy donors for intended use in any patient,
rather than from an individual patient for that patient's use, as in the case of
autologous T cells. We believe this key difference will enable us to deliver
readily available treatments faster, more reliably, at greater scale, and to
more patients.
Chimeric antigen receptor (CAR) T cell therapy, a form of cancer immunotherapy,
has emerged as a revolutionary and potentially curative therapy for patients
with hematologic cancers, including refractory cancers.
|
|
|
|